

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A/PTO

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete If Known	
(use as many sheets as necessary)				Application Number	10/609,073
				Filing Date	June 27, 2003
				First Named Inventor	Michael D. Schneider
				Art Unit	N/A 1614
				Examiner Name	Not Yet Assigned L. ROYDS
Sheet	1	of	2	Attorney Docket Number	HO-P02514US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAR	AA	US-6043254	03-28-2000	Grell et al.	
LAR	AB	US-5604251	02-18-1997	Heitsch et al.	
LAR	AC	US-6399633	06-04-2002	Dumont et al.	
LAR	AD	US-6201165	03-13-2001	Grant et al.	


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
LAR	BA	WO-9833791-A1	08-06-1998	Bristol-Myers Squibb Company	
LAR	BB	WO-0113900-A2	03-01-2001	Medicure, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
LAR	CA	Abdellatif et al, "A Ras-Dependent Pathway Regulates RNA Polymerase II Phosphorylation in Cardiac Myocytes: Implications for Cardiac Hypertrophy," Molecular and Cellular Biology, November 1998, pp. 6729-6736.		
LAR	CB	Adams et al, "Enhanced Gq Signaling: A Common Pathway Mediates cardiac Hypertrophy and Apoptotic Heart Failure," Proc. Natl. Acad. Sci. USA, Vol. 95, August 1998, pp. 10140-10145.		
LAR	CC	Akhtar et al., "Distinct Activated and Non-Activated RNA Polymerase II Complexes in Yeast," The Embo Journal Vol. 15 No. 17, 1996, pp. 4654-4664.		
LAR	CD	Bueno et al, "The MEK1-ERK1/2 Signaling Pathway Promotes Compensated Cardiac Hypertrophy in Transgenic Mice" The EMBO Journal Vol. 19 No. 23, 2000, pp. 6341-6350.		
LAR	CE	Cho et al, "A Protein Phosphate Functions to Recycle RNA Polymerase II," Genes & Development Vol. 13, 1999, pp. 1540-1552.		
LAR	CF	Chao et al, "Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication," The Journal of Biological Chemistry Vol. 275, No. 37, September 15, 2000, pp. 28345-28348.		
LAR	CG	Chao et al, "Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo," The Journal of Biological Chemistry Vol. 276, No. 34, August 24, 2001, pp. 31793-31799.		
NAL	CH	Dahmus, Michael. "Reversible Phosphorylation of the C-terminal Domain of RNA Polymerase II," The Journal of Biological Chemistry Vol. 271, No. 32, August 9, 1996, pp. 19009-19012.		
LAR	CI	Dietz et al., "Improvement of Cardiac Function by Angiotensin converting Enzyme Inhibition: Sites of Action," Circulation 1993; 87 [suppl IV]: IV-108-IV-116.		
LAR	CJ	Esposito et al, "Genetic Alterations that Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress," Circulation 2002; 105, pp 85-92.		
LAR	CK	Fu et al, "Cyclin K Functions as a CDK9 Regulatory Subunit and Participates in RNA		

Examiner Signature		Date Considered	24 OCTOBER 2005
--------------------	--	-----------------	-----------------



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
		Application Number	10/609,073		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	June 27, 2003		
		First Named Inventor	Michael D. Schneider		
		Art Unit	N/A 1614		
		Examiner Name	Not Yet Assigned L. ROYDS.		
Sheet	2	of	2	Attorney Docket Number	HO-P02514US2

LAR	CK cont.	Polymerase II Transcription," The Journal of Biology Chemistry Vol. 274 No. 49, December 3, 1999, pp. 34527-34530.	
LAR	CL	Laporte et al, "Neointima Formation After Vascular Injury is Angiotensin II Mediated," Biochemical and Biophysical Research Communications Vol. 187 No. 3, September 30, 1992, pp. 1510-1516.	
LAR	CM	Majello et al, "Control of RNA Polymerase II Activity by Dedicated CTD Kinases and Phosphatases," Frontiers in Bioscience 6, October 1, 2001, pp. 1358-1368.	
LAR	CN	Molkentin et al., "Cytoplasmic Signaling Pathways that Regulate Cardiac Hypertrophy," Annu. Rev. Physiol. 63, 2001, pp. 391-426.	
LAR	CO	Nguyen et al, "7SK Small Nuclear RNA binds to and Inhibits the Activity of CDK/Cyclin T Complexes," Nature Vol. 414, November 15, 2001, pp. 322-325.	
LAR	CP	Oh et al, "Telomerase Reverse Transcriptase Promotes Cardiac Muscle Cell Proliferation, Hypertrophy, and Survival," PNAS Vol. 98, No. 18, August 28, 2001, pp. 10308-10313.	
LAR	CQ	Orphanides et al, "A Unified Theory of Gene Expression," Cell Vol. 108, February 22, 2002, pp. 439-451.	
LAR	CR	Sano et al, "Cyclins That Don't Cycle: Cyclin T/Cyclin-Dependent Kinase-9 Determines Cardiac Muscle Cell Size," Cell Cycle 2:2, March/April 2003, pp. 99-104.	
LAR	CS	Sano et al, "Activation and Function of Cyclin T-Cdk9 (positive transcription elongation factor-b) in Cardiac Muscle-Cell Hypertrophy," Nature Medicine Vol. 8, No. 11, November 2002, pp. 1310 - 1317.	
LAR	CT	Shioi et al, "Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice," Molecular and Cellular Biology, April 2002, pp. 2799-2809.	
LAR	CU	Shioi et al, "The conserved Phosphoinositide 3-Kinase Pathway Determines Heart Size in Mice," The EMBO Journal Vol. 19, No. 11, 2000, pp. 2537-2548.	
LAR	CV	Yang et al, "The 7SK Small Nuclear RNA Inhibits the CDK9/Cyclin T1 Kinase to Control Transcription," Nature Vol. 414, November 15, 2001, pp. 317-321.	
LAR	CW	Zhang, et al, "TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice," Nature Medicine Vol. 6 No. 5, May 2000, pp. 556-563.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	24 OCTOBER 2005
-----------------------	--	--------------------	-----------------



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/609,073
				Filing Date	June 27, 2003
				First Named Inventor	Michael D. Schneider
				Art Unit	N/A 1614
				Examiner Name	Not Yet Assigned L. ROYDS
Sheet	1	of	1	Attorney Docket Number	HO-P02514US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
LAR	AA	US-20030148296-A1	08-07-2003	Brown et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
LAR	CA	Leclerc, Vincent, et al.; Dominant-negative mutants reveal a role for the Cdk7 kinase at the mid-blastula transition in <i>Drosophila</i> embryos; The EMBO Journal 19(7):1567 - 1575, 2000.		
LAR	CB	Lis, John T., et al.; P-TEFb kinase recruitment and function at heat shock loci; Genes & Development, 15:792 - 803, 2000.		
LAR	CC	Patturajan, Meera, et al.; Growth-related Changes in Phosphorylation of Yeast RNA Polymerase II; The Journal of Biological Chemistry, 273(8):4689 - 4694, 1998.		
LAR	CD	Rossi, Derrick J., et al.; Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking <i>Mat1</i> ; The EMBO Journal, 20(11):2844 - 2856, 2001.		
LAR	CE	Peng, Junmin, et al.; Identification of multiple cyclin subunits of human P-TEFb; Genes & Development, 12:755 - 762, 1998.		
LAR	CF	Shim, Eun Yong, et al.; CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the <i>C. elegans</i> embryo; Genes & Development, 16:2135 - 2146, 2002.		
LAR	CG	De Falco, Giulia, et al.; Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation; Oncogene, 19:373 - 379, 2000.		
LAR	CH	Sano, Motoaki, et al.; Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy; Nature Medicine, 8(11):1310 - 1317, 2002.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

25537270 .1		Date Considered	24 OCTOBER 2005
----------------	--	--------------------	-----------------